跳至主要内容
临床试验/NL-OMON52883
NL-OMON52883招募中4 期

A Randomized, Open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy - a strategy trial - LAX study

eids Universitair Medisch Centrum0 个研究点目标入组 110 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. Age> 18 years
  • 2. Able to give oral and written informed consent
  • 3. Presence of CIPN grade 1 or higher according to the NCIC-CTC
  • 4. Pain score of 4 or higher
  • 5. Chemotherapy with taxanes, platinums, vincalkinioids or bortezomib in the
  • 6. Presence of symptoms of neuropathic pain at least 3 months after the last
  • chemotherapy

排除标准

  • 1. Allergy to the study medication
  • 2. Epilepsy
  • 3. History of illicit drug or alcohol abuse
  • 4. History of psychosis
  • 5. Pregnancy or lactation
  • 6. Use of anti-epileptic or anti-depressant medication (in particular MAO
  • inhibitors)
  • 7. Use of CYP1a2 inhibitors (e.g. fluvoxamine, fluocinolone, cimetidine)
  • 8. Concomitant neuropathy other than chemotherapy-induced
  • 9. Moderate and severe liver enzyme abnormalities
  • 10. Kidney dysfunction (GFR < 30 mL/min)
  • 11. Severe heart failure (e.g. as a result of infarction or a structural heart
  • 12. Heart Rhythm Disorders (including 2nd or 3rd degree atrioventricular (AV)
  • block and sodium channelopathies.
  • 13. Systolic blood pressure above 180mm Hg with current antihypertensive
  • medications (according to screening measurement)
  • 14. Any condition that by the judgement of the investigator might interfere
  • with the investigation

研究者

相似试验